Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms, Hormone-Dependent 2Carcinoma, Lobular 2Carcinoma, Ductal, Breast 2Breast Neoplasms 2

Interventions

Letrozole 6Radiotherapy 4Carboplatin 4atamestane 3Trastuzumab 3Toremifene 3Magnetic Resonance Spectroscopy 3Fulvestrant 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Tamoxifen 2Paclitaxel 2Gene Expression Profiling 2Estrogen Receptor Modulators 2Capecitabine 2Aromatase Inhibitors 2Amplified Fragment Length Polymorphism Analysis 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1gallium 68 PSMA-11 1fluciclovine F-18 1entrectinib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Lobular × Estrogen Receptor Modulators × Clear all
NCT00044291 2015-07-31

Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Completed
865 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT00097344 2007-08-23

The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer

Intarcia Therapeutics

Phase 3 Terminated
842 enrolled
Breast

Breast Neoplasms, Neoplasms, Hormone-Dependent, Carcinoma, Ductal, Breast, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡